Multiple small molecule PET tracers have been developed for the imaging of the epidermal
growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the …

Despite the recent advances in cancer treatment, lung cancer remains the leading cause of
cancer mortality worldwide. Immunotherapies using immune checkpoint inhibitors (ICIs) …

Tumor heterogeneity and changes in epidermal growth factor receptor (EGFR) mutation
status over time challenge the design of effective EGFR tyrosine kinase inhibitor (TKI) …

11C-erlotinib is a PET tracer to distinguish responders from nonresponders to epidermal
growth factor receptor–targeted tyrosine kinase inhibitors and may also be of interest to …

Gadoxetate, a magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-
anion-transporting polypeptide 1B1 and multidrug resistance-associated protein 2. Six …

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate
and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is …

Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of
precision medicine with an ever increasing number of drugs directed against a variety of …

Background In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron
emission tomography (PET) using [11 C] erlotinib distinguished epidermal growth factor …

Abstract The Human Epidermal Growth Factor Receptor (ErbB/HER) family-EGFR/HER1,
ErbB-2/HER2, ErbB-3/HER3, and ErbB-4/HER4-play a key role in tumor development …

Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …